Enzene is a fully integrated end-to-end CDMO offering discovery, development, and commercial manufacturing, with integrated sites in Pune (India) and New Jersey (USA). As a pioneer in next‑generation biologics technologies, Enzene is redefining the manufacturing landscape through its patented EnzeneX™ platform, the first fully-connected continuous manufacturing™ (FCCM™) technology validated for commercial biologics supply. Partnering with innovators and biosimilar developers, Enzene accelerates time‑to‑market, enhances yields, reduces costs, and is working to bring monoclonal antibody production below $40/g.